PL2496568T3 - Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne - Google Patents
Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczneInfo
- Publication number
- PL2496568T3 PL2496568T3 PL10825954T PL10825954T PL2496568T3 PL 2496568 T3 PL2496568 T3 PL 2496568T3 PL 10825954 T PL10825954 T PL 10825954T PL 10825954 T PL10825954 T PL 10825954T PL 2496568 T3 PL2496568 T3 PL 2496568T3
- Authority
- PL
- Poland
- Prior art keywords
- substituteddihydroisoindolinone
- dioxopiperidine
- polymorph
- pharmaceutical compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102103923A CN101696205B (zh) | 2009-11-02 | 2009-11-02 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| PCT/CN2010/001751 WO2011050590A1 (en) | 2009-11-02 | 2010-11-02 | Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof |
| EP10825954.0A EP2496568B1 (en) | 2009-11-02 | 2010-11-02 | Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2496568T3 true PL2496568T3 (pl) | 2017-12-29 |
Family
ID=42141345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10825954T PL2496568T3 (pl) | 2009-11-02 | 2010-11-02 | Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9101620B2 (pl) |
| EP (1) | EP2496568B1 (pl) |
| JP (1) | JP2013509357A (pl) |
| KR (1) | KR20130026414A (pl) |
| CN (1) | CN101696205B (pl) |
| AU (1) | AU2010312224B2 (pl) |
| ES (1) | ES2634666T3 (pl) |
| PL (1) | PL2496568T3 (pl) |
| WO (1) | WO2011050590A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| CN104072476B (zh) * | 2013-03-27 | 2018-08-21 | 江苏豪森药业集团有限公司 | 泊马度胺晶型及其制备方法和用途 |
| CN104016966A (zh) * | 2014-01-30 | 2014-09-03 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000079I2 (de) | 1996-07-24 | 2010-08-12 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| EP1496878A4 (en) | 2002-04-12 | 2007-12-26 | Celgene Corp | TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2752124A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| BR0315609A (pt) | 2002-10-24 | 2005-08-23 | Celgene Corp | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| NZ540186A (en) | 2002-10-31 | 2008-03-28 | Celgene Corp | Composition for the treatment of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| UA89474C2 (uk) | 2003-05-15 | 2010-02-10 | Селджин Корпорейшн | Способи і композиції з використанням імуномодулюючих сполук для лікування і підтримки стану при раку і інших захворюваннях |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20060109979A (ko) | 2003-12-02 | 2006-10-23 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| CA2560221C (en) | 2004-03-22 | 2010-12-07 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| AU2004319758A1 (en) | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| US20050239842A1 (en) | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| JP2007536223A (ja) | 2004-05-05 | 2007-12-13 | セルジーン・コーポレーション | 骨髄増殖性疾患の治療及び管理のための免疫調節化合物を含む組成物、及びその使用方法 |
| EP1797068B1 (en) * | 2004-09-03 | 2013-10-09 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| CN101098694A (zh) | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
| ZA200704890B (en) | 2004-11-23 | 2008-09-25 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| NZ555886A (en) | 2004-12-01 | 2009-12-24 | Celgene Corp | Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders |
| CN101531653B (zh) | 2008-03-13 | 2014-07-09 | 峡江和美药业有限公司 | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 |
| TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法 |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
-
2009
- 2009-11-02 CN CN2009102103923A patent/CN101696205B/zh active Active
-
2010
- 2010-11-02 PL PL10825954T patent/PL2496568T3/pl unknown
- 2010-11-02 JP JP2012535589A patent/JP2013509357A/ja active Pending
- 2010-11-02 ES ES10825954.0T patent/ES2634666T3/es active Active
- 2010-11-02 US US13/501,437 patent/US9101620B2/en active Active
- 2010-11-02 KR KR1020127011302A patent/KR20130026414A/ko not_active Ceased
- 2010-11-02 EP EP10825954.0A patent/EP2496568B1/en active Active
- 2010-11-02 AU AU2010312224A patent/AU2010312224B2/en not_active Ceased
- 2010-11-02 WO PCT/CN2010/001751 patent/WO2011050590A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013509357A (ja) | 2013-03-14 |
| CN101696205A (zh) | 2010-04-21 |
| WO2011050590A1 (en) | 2011-05-05 |
| EP2496568B1 (en) | 2017-04-26 |
| AU2010312224A1 (en) | 2012-04-12 |
| CN101696205B (zh) | 2011-10-19 |
| ES2634666T3 (es) | 2017-09-28 |
| EP2496568A1 (en) | 2012-09-12 |
| AU2010312224B2 (en) | 2014-04-10 |
| KR20130026414A (ko) | 2013-03-13 |
| US20120203005A1 (en) | 2012-08-09 |
| US9101620B2 (en) | 2015-08-11 |
| EP2496568A4 (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL214822A0 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| PT2482812T (pt) | Composições farmacêuticas compreendendo bi-1356 e metformina | |
| IL214425A (en) | Converted metastatic heterocyclic compounds, their pharmaceutical preparations and their uses | |
| EP2254555A4 (en) | APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF | |
| EP2395975A4 (en) | ORAL PHARMACEUTICAL COMPOSITION OF DUTASTERIDE | |
| IL216388A0 (en) | New compounds, pharmaceutical composition and methods relating thereto | |
| PL2281822T3 (pl) | Nowe pochodne dihydroindolonów, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne | |
| ZA201107104B (en) | Derivatives of benzothiazines,preparation thereof and application thereof as drugs | |
| PT2504331E (pt) | Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização | |
| IL248077B (en) | Formulations, salts and polymers of transnorsertraline and their uses | |
| IL216462A (en) | Pharmaceuticals containing nitrile history and uses | |
| IL213177A0 (en) | Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide | |
| PL2496568T3 (pl) | Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne | |
| ZA201303692B (en) | Diphenyl-amine derivatives:uses,process of synthesis and pharmaceutical compositions | |
| IL211062A0 (en) | Pharmaceutical uses of lanosta-8,24-dien-3-ols | |
| GB201210536D0 (en) | Composition, use and method of preparation thereof | |
| PT2484661T (pt) | Derivado de 2,3-di-hidro-1h-inden-2-il-ureia e sua aplicação farmacêutica | |
| GB0902648D0 (en) | Pharmaceutical compounds and compositions | |
| IL219018A (en) | Radzolid Pharmaceuticals and Uses | |
| EP2626347A4 (en) | DALFAMPRIDINPOLYMORPH AND THE PREPARATION AND USE THEREOF | |
| ZA201105443B (en) | Novel saponin compounds,methods of preparation thereof,use thereof and pharmaceutical compositions | |
| EP2404588A4 (en) | PACKAGING FOR SOLID PHARMACEUTICAL PREPARATION | |
| PL2277511T3 (pl) | Kompozycje farmaceutyczne lewetiracetamu o przedłużonym uwalnianiu | |
| GB0908317D0 (en) | Pharmaceutical compounds and compositions | |
| AP2012006117A0 (en) | Pharmaceutical composition of rifampicin. |